Back to Search
Start Over
Treatment of Mycobacterium avium Complex Pulmonary Disease: When Should I Treat and What Therapy Should I Start?
- Source :
-
Clinics in chest medicine [Clin Chest Med] 2023 Dec; Vol. 44 (4), pp. 771-783. Date of Electronic Publication: 2023 Aug 14. - Publication Year :
- 2023
-
Abstract
- Treatment of M avium pulmonary disease requires a three-drug, macrolide-based regimen that is administered for 12 months beyond culture conversion. The regimen can be administered 3 days a week in non-cavitary, nodular bronchiectatic disease but should be given daily when cavitary disease is present. For treatment refractory disease, amikacin liposome inhalation suspension is added to the regimen. Parenteral amikacin or streptomycin should be administered in the setting of extensive radiographic involvement or macrolide resistance. Recurrence of disease is common and often due to reinfection. Novel and repurposed agents are being evaluated in clinical trials.<br /> (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Subjects :
- Humans
Mycobacterium avium Complex
Anti-Bacterial Agents therapeutic use
Amikacin therapeutic use
Macrolides therapeutic use
Treatment Outcome
Drug Resistance, Bacterial
Mycobacterium avium-intracellulare Infection drug therapy
Mycobacterium avium-intracellulare Infection microbiology
Lung Diseases drug therapy
Lung Diseases microbiology
Subjects
Details
- Language :
- English
- ISSN :
- 1557-8216
- Volume :
- 44
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Clinics in chest medicine
- Publication Type :
- Academic Journal
- Accession number :
- 37890915
- Full Text :
- https://doi.org/10.1016/j.ccm.2023.06.009